Scancell's Melanoma Combo Therapy Shows Improved Survival Results in Mid-stage Trial

05:42 AM EST, 12/09/2025 (MT Newswires) -- Scancell's (SCLP.L) Scope phase 2 trial for its iSCIB1+ in combination with ipilimumab and nivolumab for first-line advanced melanoma showed a continued improvement in the patients' progression-free survival. The mid-stage study showeda 74% progression-free survival at 16 months across key subgroups for the combination therapy, compared with 50% at 11.5 months for the ipilimumab plus nivolumab standard of care treatment, according to a Tuesday release. The trial also reported a 14% improvement in early overall survival at 26 months over standard of care therapy. The immunotherapies company added that it is continuing its "positive discussions" with the US Food and Drug Administration and other regulators for the combination therapy's phase 3 trial design, dose, manufacturing, and endpoint details, and noted that it is actively engaging potential partners for the next stage's funding.